Low MHC‑I expression remains a major barrier to effective tumour immunotherapy, especially in paediatric cancers. This review outlines mechanisms of MHC‑I downregulation and emerging approaches to restore antigen presentation. 📄 https://bit.ly/45vtfmp

Support @imtadvances.bsky.social in advancing immunotherapies for neurodegenerative & CNS immune-mediated diseases. We welcome original research, reviews, and clinical trial protocols on therapeutic development in neuroimmunology: oxford.ly/4pBKPwp #ImmunoSky #Immunotherapy

Can blood‑based T‑cell markers predict PD‑1 therapy response in melanoma? This study suggests yes, highlighting CD8⁺ proliferation in responders and CTLA‑4⁺ Tregs in non‑responders. Read here📄 https://bit.ly/4pw1rVL

🚀 Submit your work to the Neuroimmunology & Immunotherapy Special Collection Covering neurodegeneration, neuroinflammation, immune checkpoints, gut–brain axis, and more. Deadline: March 2026. Learn more: https://bit.ly/4psT5hG

Tumour‑reactive plasma cells are emerging as powerful players in cancer immunotherapy. This review highlights their role, the promise of neoantigen‑reactive PCs, and the challenges in epitope prediction and screening. 📄 https://bit.ly/3SVZsMC

Happy holidays from all of us! ❄️✨ Thank you to our authors, reviewers, and readers for another great year. We look forward to welcoming your submissions in the new year!

Natural killer cells are gaining momentum in cancer immunotherapy. This open-access review in Immunotherapy Advances explores how CAR-NK cells, NK engagers, cytokines and checkpoint inhibitors are being harnessed to boost anti-tumour immunity. 🔗 https://bit.ly/4j8dKEW

🎧 ITA Wrapped! A standout year for Immunotherapy Advances! Thank you to our authors, reviewers and readers for helping ITA grow its reach and impact in 2025.

Congratulations to the winners of the BSI journals-sponsored Poster Prizes! 🎉 Flavio Beke, Aisling Newing & Rébecca Barascud delivered outstanding research.👏 Full details here 👉 https://bit.ly/3MljD6r

Attending #BSI25?📣 Don’t miss AI in Publishing with Rachel Moriarty from our publisher OUP. Explore how AI is shaping journals, research integrity & ethical practice, plus tips for using AI responsibly as an author. 🗓 3 Dec 2025 | ⏰ 13:15–14:10 | 📍 Hall 1C ##Immunology

Read 'Knowledge-based immune-therapeutic advances for transplantation and cancer' by Elizabeth Simpson here: doi.org/10.1093/imma...

Congratulations Liz! Read her historical perspective article in @imtadvances.bsky.social

Since 1986, CD40’s role in #immunity has expanded. @imtadvances.bsky.social's upcoming collection will explore therapeutic targeting of CD40/CD154. Submit your work to get involved: oxford.ly/3M5mYqo#immunity #ImmunoSky #Immunotherapy

🛡️ This #PublishingIntegrityWeek, BSI journals are tackling papermills, promoting AI transparency, DEI & accessibility, and supporting ethical research in immunology. Read more 👉 https://bit.ly/4odyvAZ

New review by Blee et al. “Turning the Tide: Harnessing Vaccines & Viruses to Fight Cancer” 🚀 How advanced preclinical models can boost cancer vaccines & oncolytic viruses 👉 https://bit.ly/4oLO7Nk ##CancerResearch #Immunotherapy

🧬 Therapeutic cancer vaccines are back in focus! Advances in neo-antigen T cells, dendritic cell biology, and mRNA tech are paving the way for next-gen immunotherapy. Read the Open Access review: https://bit.ly/4cefxGm #CancerVaccines #Immunotherapy #mRNA #Oncology

🦠 DC3s in solid tumours can prime T cells and influence outcomes—boosting survival in some cancers, but promoting immunosuppression in others. 👉 https://bit.ly/3T2blRg ##Immunotherapy #CancerImmunology

🔬 First head-to-head comparison of nuclear imaging for tumour CD8⁺ T cells shows [⁸⁹Zr]Zr-anti-CD8-IgG2a(silent) & [⁸⁹Zr]Zr-OT-I track T-cell infiltration & migration, aiding immunotherapy strategies. 👉 https://bit.ly/4ncWCzv ##Immunotherapy #CD8Tcells #CancerResearch

From CAR-NK cells to checkpoint inhibitors, Blunt & Khakoo review how boosting NK-cell function could transform cancer therapy. 🔓 Open access: https://bit.ly/4j8dKEW #Immunotherapy #NKcells #CancerResearch

New study shows switching between Humira® and AVT02 in chronic plaque psoriasis does not alter cellular immunogenicity. Novel EVCIA approach confirms comparable T cell responses, supporting interchangeability. 🔗 Open access: https://bit.ly/3J8pESs #Immunology #Psoriasis

Tracking CD8+ T cells in tumours is key for immunotherapy research. Our new study compares nuclear imaging methods to see which best reflects T cell infiltration. 🔗 Open access: https://bit.ly/4ncWCzv #Immunotherapy #CD8TCells #CancerResearch

🏆Following last week's exciting #NobelPrize announcement, the BSI journals have created a new virtual issue. 🔎Check it out for must-read articles on peripheral immune tolerance, including a paper from Nobel Laureate Shimon Sakaguchi: immunology.org/publications...

🧬 New in Immunotherapy Advances: Cytokine-induced memory-like NK cells + Tafasitamab show strong efficacy against B-cell ALL, boosting cytotoxicity & survival in vivo. Open Access 👉 https://bit.ly/48oztXa ##Immunotherapy #NKcells

🧬 Low MHC-I expression can help tumours evade the immune system. Discover strategies to boost MHC-I and improve immunotherapy in paediatric and adult cancers. 🔬 Read: https://bit.ly/45vtfmp #Immunotherapy #CancerResearch #MHCI

💡 Tumour-reactive plasma cells are emerging as powerful players in cancer immunotherapy! Explore their role in antibody-based, personalized treatments. 🔬 Read: https://bit.ly/3SVZsMC #Immunotherapy #CancerResearch #PlasmaCells

💥Open Access review: NK cells as cancer fighters! From CAR-NK cells to checkpoint inhibitors, explore cutting-edge strategies to harness NK-cell immunity. 🔬 Read: https://bit.ly/4j8dKEW #Immunotherapy #NKcells #CancerResearch

Could CD200R blockade enhance PD-1 therapy? A humanised mouse study found limited benefit in colorectal & lung cancer, but points to potential in CD200⁺ tumours. 🔗 https://bit.ly/4pdAtDw #Immunotherapy #CancerResearch

Exploring the role of DC3s in solid tumours! These dendritic cells can boost anti-tumour immunity or contribute to immunosuppression depending on the TME. Discover their potential for targeted therapies 👉 https://bit.ly/3T2blRg #EMDS2025 #Immunotherapy #CancerResearch

TAMs drive tumour progression, metastasis & therapy resistance. Targeting their surface receptors may unlock new cancer immunotherapy strategies, insights for #EMDS2025 🔗 https://bit.ly/4i95qnm

Could JAK inhibitors be a treatment for STAT3 gain-of-function? Study shows symptom improvement in patients with this rare immune disorder. Read here🔗 https://bit.ly/4p7Vxer #Immunotherapy

⏳ Last chance! Submit your research on immunotherapies for inborn errors of immunity to our Special Collection before the end of September. Submit here: https://bit.ly/4p96dJA ##Immunology

It's the final day of Cancer Immunology: Advances & Therapeutic Application, don’t miss our journals manager Laura Franklin giving a talk at 11:00 AM today! Learn more about publishing opportunities and journal initiatives. ##CancerImmunology #Immunotherapy

Are you attending Cancer Immunology: Advances & Therapeutic Application and working on cancer vaccines? Share your latest research in our Special Collection on global advances, personalised or off-the-shelf vaccines, clinical trials & more. Submit here: https://bit.ly/4mPbW64

Attending Cancer Immunology: Advances & Therapeutic Application? Come and visit us at our booth to learn more about our journals, upcoming special collections, and opportunities to publish! #CancerImmunology #Immunology

NLRP3 inflammasome activation in sensory neurons drives chronic inflammatory & osteoarthritis pain. Blocking this pathway may offer a route to new treatments. Read more🔗 https://bit.ly/3UX7Tbz #ChronicPain #Immunology

Working on targeted therapies for inborn errors of immunity? Our Special Collection on genetics-guided immunotherapy closes at the end of this month, submit your research today! Learn more: https://bit.ly/4p96dJA

🚀 Going viral against #Glioblastoma! Discover how oncolytic viruses are reshaping the immune landscape of GBM, boosting therapy response & offering new hope. Open Access 👉 https://bit.ly/3UMBhkw #Immunotherapy #CancerResearch

High-affinity TCR bispecific (ImmTAC®) redirects T cells to efficiently kill PRAME+ tumor cells across multiple cancers. Combination with PD-1 blockade may enhance activity. By Ribeiro et al. 🔗 https://bit.ly/40o5kT8 ##Immunotherapy #CancerResearch #PRAME

💉 During #ImmunisationAwarenessMonth, a timely reminder: mRNA COVID-19 vaccines (Pfizer & Moderna) remain highly effective at preventing hospitalisation (84–86%), even with variant challenges. 🔗 https://bit.ly/43rUWvP ##Vaccineswork #immunology

💉 Cancer vaccines are regaining momentum with advances in neoantigen science, tumour mutational burden & mRNA technology. A deeper understanding of dendritic cells and immune mechanisms is key to unlocking their full potential. 🚀 ##ImmunisationAwarenessMonth 🔗 https://bit.ly/4cefxGm

Why are paediatric tumours less responsive to immunotherapy? One reason: MHC-I downregulation. Restoring it could make tumour cells visible again to CD8 T cells. 🔗 https://bit.ly/45vtfmp

Smallpox vaccines provide important cross-protection against Mpox. Evidence from past outbreaks informed the use of the MVA–BN vaccine during 2022, highlighting how immunisation strengthens preparedness for emerging threats. ##NationalImmunisationAwarenessMonth 👉 https://bit.ly/4jSbodz

Bispecific T-cell engagers (BiTEs) redirect T-cells to attack tumors, but their power is often limited by immune checkpoints & suppressive microenvironments. 💡 Combination strategies with checkpoint inhibitors, chemo, or oncolytic viruses could boost effectiveness. 👉 https://bit.ly/4oKabbt

🌟 Researchers in cancer immunology: showcase your work in our Special Collection: Cancer Vaccines Global Advances! Submit studies, reviews, or clinical updates on personalized & off-the-shelf vaccines. Deadline: Dec 2025. ##CancerResearch #Immunotherapy

Did you know? 🩺 Patients on immune checkpoint inhibitors can develop inverse psoriasis, often mistaken for fungal infections. Early recognition by oncologists & dermatologists is key to better care. 🧴🩹 ##NationalPsoriasisMonth #Psoriasis 🔗 https://bit.ly/4lw91iq

Liu et al. show that SMAC mimetics + IFNγ can reprogram human macrophages to phagocytose live pancreatic & breast cancer cells, revealing a TNFα-driven feedback loop that sustains this activity. Read now🔗 https://bit.ly/4mBGMix #Immunotherapy #CancerResearch

📅 August is #NationalPsoriasisMonth 🧬 Study finds similar immune responses in chronic plaque psoriasis patients on Humira® whether they stayed on it or switched with AVT02, supporting interchangeability. 🔗 https://bit.ly/3J8pESs

Tumour-reactive plasma cells (TRPCs) are emerging as potent players in cancer immunotherapy 🧬🧪 Chen et al explore their potential, challenges in neoantigen targeting, and prospects for personalised therapy. 📖 https://bit.ly/3SVZsMC #Immunotherapy #CancerResearch

🧠 Can viruses turn the tide in glioblastoma treatment? Oncolytic virus therapy shows promise in reshaping the tumour microenvironment and boosting immune response in GBM. Explore the latest insights and clinical trial findings: https://bit.ly/3UMBhkw ##Immunotherapy

Studying cancer vaccines? 🎯 Submit your latest research to our Cancer Vaccines Global Advances Special Collection! Showcase personalized & off-the-shelf vaccines, clinical trials & more. Deadline: Dec 2025 Learn more & submit: https://bit.ly/45mr1m8 ##Immunotherapy